WO2005058951A1 - 糖鎖欠損型肝細胞増殖因子 - Google Patents
糖鎖欠損型肝細胞増殖因子 Download PDFInfo
- Publication number
- WO2005058951A1 WO2005058951A1 PCT/JP2004/018719 JP2004018719W WO2005058951A1 WO 2005058951 A1 WO2005058951 A1 WO 2005058951A1 JP 2004018719 W JP2004018719 W JP 2004018719W WO 2005058951 A1 WO2005058951 A1 WO 2005058951A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sugar chain
- growth factor
- amino acid
- hepatocyte growth
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Definitions
- the present invention relates to a sugar chain deficient hepatocyte growth factor. More specifically, the present invention relates to a hepatocyte growth factor modified by deleting a sugar chain of hepatocyte growth factor.
- Hepatocyte growth factor (hereinafter also referred to as HGF) is a protein having proliferative activity of liver parenchymal cells, and one having a different amino acid sequence has been reported, and its name is SF (scatter factor), TCF (Tumor cytotoxic factor), etc. are used.
- these proteins having known hepatocyte proliferation activity are collectively referred to as HGF.
- HGF is known to be a physiologically active peptide which exhibits various pharmacological actions such as cell migration promotion, morphogenesis promotion, angiogenesis action, neuroprotective action or anti-apoptotic action as well as proliferation of hepatocytes. (See Non-Patent Document 1).
- HGF is its pharmacological action
- Therapeutic agents for liver cirrhosis agents for treating renal diseases, agents for promoting proliferation of epithelial cells, anticancer agents, agents for preventing side effects for cancer therapy, agents for treating lung disorders, agents for treating gastric and duodenal injuries, treating cranial nerve disorders
- Agent immunosuppressive side effect preventive agent, collagen degradation promoter, agent for treating cartilage disorder, agent for treating arterial disease, agent for treating pulmonary fibrosis, agent for treating liver disease, agent for treating blood coagulation abnormality, agent for treating low blood plasma, agent for treating wound It is expected to be developed as a neuropathy improving agent, a hematopoietic stem cell increasing agent, a hair growth promoting agent and the like (see, for example, Patent Documents 1-14).
- HGF is secreted from organs such as liver, brain, lung, bone marrow, spleen, placenta or kidney, or from blood cells such as platelets and white blood cells, but since it is present only in extremely small amounts in the living body, HGF In order to use it as a pharmaceutical preparation, it is necessary to produce in large quantities using cells by genetic engineering techniques. Conventionally, it is known that HGF can be produced using animal cells such as Chinese hamster ovary (CH ⁇ ) cells (see Patent Documents 15 and 16). However, in general, methods for producing proteins using animal cells such as CHO cells are considered to be expensive and lead to an increase in drug prices.
- CH ⁇ Chinese hamster ovary
- Yeast is known as a host capable of inexpensively producing proteins and as a cell having an ability of glycosylation (see Non-patent Literature 8-10). Since yeast is a eukaryote and has an endoplasmic reticulum and a Golgi apparatus, it has a sugar chain biosynthesis mechanism. However, since the sugar chain biosynthesis mechanism of yeast is largely different from that of animal cells, when a protein having a glycosylation site is produced in yeast, yeast-type sugar chains are added. It is known that the sugar chain structure of yeast is greatly different from those of human and other mammals (see Non-patent Document 11).
- insect cells are also hosts having glycosylation ability, and the ability to produce proteins at relatively low cost S ability to be able to differ in the sugar chain structure of insect cells from human-type sugar chain structures It is known (see Non-Patent Document 12).
- insect cells may also exhibit antigenicity to humans and other mammals.
- HGF has five sugar chains attached thereto (see Non-Patent Documents 13 and 14). If the sugar chain of HGF is removed, the effect on the activity will be produced, for example, by culturing Tumi-fumicin, an inhibitor of N-linked glycosylation, when added to HGF-producing cells. It has been reported that HGF retains cell migration activity (in the article, HGF is expressed as SF) (see Non-Patent Document 15).
- HGF In addition to cell migration activity, HGF has a wide range of activities such as cell proliferation, morphogenesis promotion, angiogenesis, anti-cell death activity or neuroprotection (see Non-patent Document 16). It is difficult to say that HGF deficient in sugar chain has cell migration activity and also has other functions. For example, NK2, which is a truncated variant of HGF, has cell migration activity but not cell proliferation activity (see Non-patent Document 17).
- HGF retains various functions when the sugar chain of HGF is deleted. Since HGF has various activities, it is considered to be a biorepair factor, and it was not considered that the deletion of the sugar chain of HGF would not affect the high function of HGF.
- Patent Document 1 Japanese Patent Application Laid-Open No. 4-18028
- Patent Document 2 Japanese Patent Application Laid-Open No. 4-49246
- Patent Document 3 European Patent Application Publication No. 492614
- Patent Document 4 Japanese Patent Application Laid-Open No. 6-25010
- Patent Document 5 International Publication No. 93/8821
- Patent Document 6 Japanese Patent Application Laid-Open No. 6-172207
- Patent Document 7 Japanese Patent Application Laid-Open No. 7-89869
- Patent Document 8 Japanese Patent Application Laid-Open No. 6-40934
- Patent Document 9 International Publication No.
- Patent Document 10 Japanese Patent Application Laid-Open No. 6-40935
- Patent Document 11 Japanese Patent Application Laid-Open No. 6-56692
- Patent Document 12 Japanese Patent Application Laid-Open No. 7-41429
- Patent Document 13 International Publication WO 93/3061 Brochure
- Patent document 14 Unexamined-Japanese-Patent No. 5-213721 gazette
- Patent Document 15 Japanese Patent Application Laid-Open No. 11-4696
- Patent Document 16 Japanese Patent Application Laid-Open No. 10-191991
- Non-patent literature 1 Matsumoto 'K (Matsumoto, K) et al., Kidney ⁇ ⁇ ⁇ (Kidney International), 2001, 59, p.
- Non-Patent Document 2 Swartz 'Ji'ar (Swarts, JR), Current' Opinion 'in' Nano Technology (Current opinion in biotechnology), 2001, 12th ed., P. 195-201
- Non-patent document 3 Cornfeld 'R (Komfeld, R.) et al., 1 person,' functional 'review,' ab 'biochemistry (Annual review of biochemistry.), 1985, 54th, p. 631-664
- Non-Patent Document 4 Kobata 'A (Kobata, A.), Yo-bit Bian' Journal 'Ob' 'Biochemistry' (European journal of biochemistry), 1992, 209, ⁇ ⁇ 483 — 501
- Non-Patent Document 5 Birki 'A (Varki, A.), Glycobiology, 19 93, 3rd ed., P. 97-130.
- Non-patent document 6 Goochy, C. F. et al., Biotechnologies (Biot echnolgy), 1991, 9th, p. 1347-1355
- Non-Patent Document 7 Takeuchi 'M (Takeuchi, M.) et al., 1 person, Glycobiology, 1991, 1st report, p. 337-346
- Non-Patent Document 8 Wisman A. (Wiseman A.), Endeavor., 1 996, 20, p. 130-132.
- Non-Patent Document 9 Russell, C., et al., Australian 'Journal' biotechnology (Australian journal of biotechnology, 1991, 5th ed., P. 48-55
- Non-Patent Document 10 Buckholz, R. G., et al., 1 person, Biotechnology, 1991, 9th, p. 1067-1072
- Non-Patent Document 11 Gemmill, T. R. M., 1 person, Biochemica 'Eto', Biooffica force 'Akta (Biochimica et biophysica acta), 1999, No. 1426, p. 227-237
- Non-patent literature 12 Altmann 'F (Altmann, F. et al., Glycoconjugate' journal)
- Non-patent literature 13 Hara 'Eichi (Hara, H. et al., Journal' ob 'biochemistry). urnal of biochemistry), 1993, 114, p. 76- 82
- Non-patent literature 14 Shimizu 'N (Shimizu, N.) et al., Biochemical' and 'biofuel force nore' Lisa 1 -chi 'co-uni-shi-shionsu, Biochemical ana biophvsica research communications), 1992, 189, p. 1329-1335.
- Non-Patent Document 15 Hoffmann 'R (Hofmann, R.) et al., Biochemica' Et 'Biophysica * acta (Biochimica et biophysica acta), 1992, No. 1120, p. 343-350
- Non-Patent Document 16 Matsumoto 'K (Matsumoto, K.) et al., 1' Biochemical 'and' Biometrical Nore 'Research' Communications (Biochemical and biophysical search communications), 1997, 239, p. 639 —644
- Non-Patent Document 17 Hartmann 'G (Hartmann, G. et al., Proceeding' Ob 'the' Nashonare 'Aka Kademi One Ob Science' Ob The The United '' State 'Ob' Amely Power (Proceedings oi the National Academy of Sciences of the Unites States of America, 1992, 89, p. 11574-11578
- An object of the present invention is to provide a sugar chain deficient hepatocyte growth factor in which the sugar chain of HGF is deleted, and to provide a method for producing the same.
- the present inventors have made extensive researches on the sugar chain function of HGF in order to solve the above-mentioned problems, and as a result, they have found that even if the sugar chain of HGF is removed, the function of HGF is maintained. It was quite unexpected that a protein with high function such as HGF retains the function even after removing the sugar chain. On the contrary, the glycan-deficient HGF has improved stability in blood as compared to HGF having a sugar chain, and such a fact was a totally surprising discovery. Based on the above findings, the present inventors have further studied to complete the present invention.
- a sugar chain deficient hepatocyte growth factor characterized in that a sugar chain is deleted in all or at least one site of the glycosylation site of the hepatocyte growth factor
- the sugar chain is not added at position 294 by substituting the amino acids at positions 294 and / or 296 with other amino acids or the amino acids at Z and 295 with Pro; b) The sugar chain is not added at position 402 by substitution of the amino acid at position 402 or / and position 404 with another amino acid, or by substitution of the amino acids at position Z and position 403 with Pro; c) no glycosylated at position 476 due to substitution of the amino acid at position 476 with another amino acid;
- glycosylated form is not added at position 566 by substitution of the amino acid at position 566 and / or 568 with another amino acid or / and amino acid at position 567 with Pro; Or
- a sugar chain is not added at position 653, as a result of substitution of amino acids at positions 653 or Z and 655 with other amino acids, and / or substitution of an amino acid at position 654 with Pro. as well as
- hepatocyte growth factor according to any of (1) to (4) above, which is modified based on the amino acid sequence set forth in SEQ ID NO: 2, which corresponds to the amino acid in SEQ ID NO: 2
- a sugar chain deficient hepatocyte growth factor characterized in that at least one or more of the modifications shown in the following a) to e) are made;
- glycosylated form is not added at position 289 by substitution of the amino acid at position 289 or / and amino acid 291 with another amino acid or / and / or amino acid 290 at Pro; b) A sugar chain is not added at position 397 by substitution of the amino acid at position 397 or / and amino acid 399 with another amino acid or / and amino acid at position 398 with Pro; c) The sugar chain is not added at position 471 by substitution of the amino acid at position 471 with another amino acid;
- a sugar chain is not added at position 561 by substitution of the amino acid at position 561 and / or 563 with another amino acid or / and amino acid at position 562 with Pro; Or
- a sugar chain is not added at position 648 by substituting the amino acids at positions 648 or Z and 650 with other amino acids or / and the amino acid at position 649 with Pro, About.
- a DNA comprising a nucleotide sequence capable of encoding the sugar chain deficient hepatocyte growth factor according to any one of (1) to (7) above,
- the vector described in (9) above is introduced into an insect individual to produce a sugar chain deficient hepatocyte growth factor in the insect individual, and the sugar chain deficient hepatocyte growth factor is purified and recovered from the insect individual.
- sugar chains are completely or partially removed by treating liver cell growth factor having sugar chains with an enzyme, and sugar chain deficient hepatocyte growth factor is purified and recovered from the enzyme reaction solution.
- a gene comprising a vector incorporating a DNA sequence containing a nucleotide sequence encoding a hepatocyte growth factor having a sugar chain or the vector described in (9) above is introduced into a cell not capable of glycosylation and the cells are cultured. And producing a sugar chain-deficient hepatocyte growth factor in the cell or in the culture solution of the cell, and purifying and recovering the sugar chain-deficient liver cell growth factor in the cell or in the culture solution of the cell.
- a method for producing a sugar chain deficient hepatocyte growth factor according to any one of (1) to (7) above, characterized in that
- a sugar chain-deficient hepatocyte growth factor is synthesized by the cell-free protein synthesis system using a nucleotide sequence encoding a hepatocyte growth factor having a sugar chain or a gene consisting of the nucleotide sequence according to (8) as a template.
- a gene therapeutic agent comprising the DNA according to (8) above,
- the sugar chain deficient HGF of the present invention has the same activity as HGF having a sugar chain in cell proliferation activity, cell migration activity or morphogenic activity, etc., and the temperature stability is also equivalent. Can be a substitute for HGF. Therefore, the pharmaceutical preparation containing the glycan-deficient HGF of the present invention as an active ingredient has the same use as that of HGF having a sugar chain, that is, a mammal (for example, human, dog, cat, rat, mouse, rabbit, (Uma, Ushi, Hedge, guinea pig, etc.), liver cirrhosis treatment agent, renal disease treatment agent, epithelial cell proliferation promoter, anticancer agent, anti-cancer agent side effect agent, lung disorder treatment agent, stomach ⁇ duodenum Therapeutic agents for injury, cranial nerve disorder, immunosuppressive side effects, collagen degradation promoters, agents for treating cartilage disorders, agents for treating arterial disease, agents for treating pulmonary fibrosis, agents for treating liver disease, agents for treating blood coagul
- the medicament containing the DNA encoding the sugar chain deficient HGF of the present invention can be used as a gene therapeutic drug for the above-mentioned diseases.
- the sugar chain deficient HGF of the present invention is more stable in blood than HGF having a sugar chain, the dose of HGF can be reduced, and the side effects due to HGF can be prevented.
- the sugar chain deficient HGF of the present invention can be produced in yeast or insect cells, and therefore can be produced inexpensively.
- FIG. 1 shows the results of analysis of each HGF by SDS-PAGE. After each HGF was reduced and run, the gel was stained with silver.
- FIG. 2 is a graph showing the growth activity of HGF in hepatocyte proliferation, and the amount of DNA synthesis in rat hepatocytes as an indicator.
- FIG. 3 The cell migration activity of HGF was compared according to the degree of dispersion of MDCK cells It is a figure which shows a result.
- FIG. 4 shows the results of comparison of the morphogenic activity of HGF according to the degree of lumen formation of MDCK cells.
- FIG. 5 is a diagram showing the temperature stability of HGF. Each HGF was incubated at 37 ° C for the indicated number of days. The residual activity was measured using the amount of DNA synthesis of rat hepatocytes as an index and expressed as a relative value.
- FIG. 6 shows the stability of HGF in blood.
- the sugar chain deficient type HGF is a glycosylation site of a mammal having a sugar chain, for example, human, dog, cat, rat, mouse, rabbit, dog, dog, guinea pig or the like. HGF whose structure has been modified such that all or at least one of the sugar chains in the group is deleted.
- one or several amino acids in the amino acid sequence in which a mutation is introduced so as not to add a sugar chain to known HGF are deleted, substituted, added or Also included are proteins having an inserted amino acid sequence and having HGF activity.
- a protein having at least about 60% or more homology with the amino acid sequence to which mutation has been introduced so as not to add a sugar chain to known HGF preferably A protein having about 80% or more homology, more preferably a protein having about 90% or more homology, even more preferably a protein having about 95% or more homology, and having HGF activity included.
- the phrase "deletion, substitution, addition or insertion of one or several amino acids” means a number that can be naturally produced by known technical methods such as site-directed mutagenesis. Means that it has been deleted, substituted, added or inserted.
- homology in the above amino acid sequences refers to the degree of matching of the amino acid residues constituting the respective sequences by comparing the primary structures of the proteins and comparing the sequences.
- the sugar chain-depleted HGF of the present invention can be obtained by introducing into a cell a vector incorporating a mutated HGF gene such that a sugar chain is not added at at least one site of the glycosylation site of HGF.
- the sugar chain-deficient HGF of the present invention can also be obtained by introducing a vector containing the nucleotide sequence of HGF having a sugar chain into a cell without the ability to add sugar.
- amino acids used for conversion it is preferable to appropriately select amino acids that do not form a new consensus sequence with the amino acid sequences before and after the above consensus sequence.
- mutations may be introduced into the nucleotide sequence such that proline is introduced at the X site in the consensus sequence.
- the glycosylation site in HGF is Asn (N-linked sugar chain) at position 294 and Asn (N at position 402 of the amino acid sequence shown in SEQ ID NO: 1 in the sequence listing. — (Linked sugar chain), 476 Thr (O-linked sugar chain), position 566 Asn (N-linked sugar chain), and position 653 Asn (N-linked sugar chain).
- the glycosylation site in 5-amino acid-deleted human HGF represented by SEQ ID NO: 2 in the sequence listing is Asn at position 289 (N-linked sugar chain) , Asn at position 397 (N-linked sugar chain), Thr at 471 ( ⁇ 1-linked sugar chain), Asn at position 561 (N-linked sugar chain), Asn at position 648 (N -Linked sugar chains).
- the above consensus sequence of the above human HGF is the position 294 to position 296, the position 402 to the position 404, the position 566 to the position 568, and the position 294 to the amino acid sequence shown in SEQ ID NO: 1 in the sequence listing. It is from 653 to 655.
- the consensus sequence is the positions 289 to 291, 397 to 399, and 561 to 563 of the amino acid sequence shown by SEQ ID NO: 2 in the sequence listing. And it is from the 648th position to the 650th position.
- the DNA is cut out by a restriction enzyme from the thus obtained DNA encoding the amino acid sequence of the glycan-depleted HGF or a recombinant vector such as a plasmid or a phage containing the DNA encoding the amino acid sequence of HGF having a sugar chain
- a recombinant expression vector can be prepared by religation using a restriction enzyme and a DNA ligase downstream of the promoter of a vector suitable for expression of sugar chain deficient HGF.
- nucleotide sequences encoding (1) promoter, (2) ribosome binding site, (3) initiation codon, and (4) the sugar chain deficient HGF of the present invention if necessary
- a recombinant expression vector is constructed to contain DNA, (5) stop codon, (6) terminator and the like.
- DNA consisting of a nucleotide sequence encoding a carbohydrate-deficient HGF in which a mutation is introduced at the above-mentioned glycosylation site is added (a) 1 of the bases of the nucleotide sequence encoding the above-mentioned carbohydrate-deficient HGF Or a DNA encoding a protein having an HGF activity and having a nucleotide sequence in which several bases have been deleted, substituted, added or incorporated, (b) a nucleotide sequence encoding the aforementioned sugar chain deficient HGF DNA consisting of a nucleotide sequence complementary to the DNA having the DNA and a nucleotide sequence hybridizing under stringent conditions and encoding a protein having HGF activity, or (c) a base encoding the aforementioned sugar chain deficient HGF Also included is a DNA consisting of a nucleotide sequence encoding a protein having at least about 60% or more homology with
- nucleotide sequence may be naturally occurring or may be naturally occurring by well-known technical methods such as site-directed mutagenesis when "one or several bases are deleted, substituted, added or inserted”. It means that a certain number of bases are deleted, substituted, added or inserted.
- the DNA capable of hybridizing under stringent conditions means the colony 'no hybridization' method, the plaque 'no hybridization' method, or the Southern blot Ibrida, using the above DNA as a probe. It means DNA obtained by using the imaging method or the like.
- a salt concentration for example, an about 0.1-fold concentration of SSC solution (the composition of the 1-fold SSC solution is composed of 150 mM sodium chloride and 15 mM sodium citrate).
- Hybridization conditions at a temperature of about 65 ° C.
- the DNA having the homology is a DNA having at least about 60% homology, preferably about 80% or more, more preferably about 90% or more, under high stringency conditions. It refers to DNA having sex, more preferably DNA having homology of about 95% or more.
- the sodium concentration is about 19 to 40 mM, preferably about 19 1 to 20 mM
- the temperature is about 50 to 70 ° C., preferably about 60 to 65 ° C. I say the condition.
- a sodium concentration of about 19 mM and a temperature of about 65 ° C. are the most preferable conditions.
- vectors examples include plasmids such as pBR322, pUC18 and pUC19 (Toyobo) when using E. coli as a host, and plasmids such as pUB 110 (Sigma) when using B. subtilis as a host.
- plasmids such as pBR322, pUC18 and pUC19 (Toyobo) when using E. coli as a host
- plasmids such as pUB 110 (Sigma) when using B. subtilis as a host.
- yeast When a yeast is used as a host, a plasmid such as pYES2 (Invitrogen) or pRB15 (ATCC37062) can be used.
- pCAGGS or pCXN2 Niwa, H., Yamamura, K. and Miyaza ki, J., Gene, 1991, No. 108, p.
- pcDL-SRa Takebe, Y. et al., Mol. Cell. Biol., 1988, 8th ed., P. 466-472
- vectors derived from bacteraio phages lgt10, gtll (Stratagene), virus SV40 (BRL), BPV (ATCC VR-703) or a retrovirus gene, etc.
- replication within the host is possible.
- ⁇ It is especially limited if it is an amplifiable vector It is not fixed.
- the promoter or terminator is not particularly limited as long as it corresponds to the host used for expression of the nucleotide sequence encoding the sugar chain deficient HGF.
- Examples of the promoter include trp promoter, lac promoter, rec A promoter, ⁇ PL promoter or lpp promoter when the host is E. coli, and PH05 promoter, PGK promoter, GAP when the host is yeast. Promoter or ADH promoter etc. may be mentioned.
- rous sarcoma virus virus RSV
- MPSV polymeric virus
- avian sarcoma virus cytomegalovirus
- SMV cytomegalovirus
- promoters obtained from viral genomes such as simian virus 40 (SV40) or vaccinia virus, merothionein promoter or heat shock promoter.
- an enhancer is introduced into the vector. Transfer is enhanced by the introduction of enantiomers.
- enhancers include SV40 enhancer, cytomegalovirus early promoter / enhancer, adenovirus enhancer or adenovirus enhancer.
- terminator if the host is E. coli, ti "p terminator or lpp terminator, etc., if the host is Bacillus subtilis, amyF terminator, etc .; if the host is yeast, CYC1 terminator, etc. When it is an animal cell, it may be exemplified SV40 terminator or HSV1TK terminator etc. It is preferable to use these promoters and terminators appropriately in combination depending on the host used.
- the sugar chain deficient HGF expression vector constructed in this manner can be obtained by the combinatorial cell method CJ.
- Examples of cells that can be used as a host include, but are not particularly limited to, cells of animals, plants, insects, nuclear microorganisms or eukaryotic microorganisms. These cells may form an individual, and may be an animal, a plant or an insect as a host. In animal cells, either adherent cells or floating cells can be used, and animal cells that produce and accumulate sugar chain deficient HGF in cells or animals that secrete and produce sugar chain deficient HGF extracellularly Even cells, please. For example, CHO cells (Chinese Nomster ovary cells), COS cells, BHK cells, mouse C127 cells, Hela cells and the like can be mentioned.
- Examples of plant cells include rice, tobacco and Arabidopsis thaliana, and examples of insect cells include cells such as Sf9 and Sf21.
- examples of insects for example, silkworm can be mentioned.
- Examples of prokaryotic microorganisms include Escherichia coli and Bacillus subtilis, and examples of eukaryotic microorganisms include yeasts such as Saccharomyces cerevisi ae, ⁇ chizosaccharomyces pombe, and ida boidinii f or Pichia pastoris or filamentous fungi such as Aspergillus, Trichoderma or Mucor. It is possible to do S.
- it is a yeast, an insect cell or an insect individual.
- prokaryotic cells since there is no glycosylation ability, HGF gene having wild type sugar chain is introduced.
- the resulting transformant is cultured in an appropriate medium depending on the host in order to produce the target sugar chain deficient HGF.
- the medium contains a carbon source, a nitrogen source, inorganic substances, vitamins, serum, drugs and the like necessary for the growth of the transformant.
- the medium when the host of the transformant is E. coli, LB medium (Nissui Pharmaceutical) or M9 medium Exp. Mol. Genet., Cold Spring Laboratory, New York, 1972, p.
- YEPD medium Genetic Engineering, No. 1; Plenum Press, New York, 1979, p. 117
- MEM medium modified Eignore medium
- DMEM medium Dalbecco modified Eagle medium
- RPMI 1640 medium RPMI 1640 medium
- Culturing of transformants is usually performed at about 20 ° C. and 45 ° C.
- pH is in the range of about 5-8
- aeration and agitation are performed as needed.
- glass beads, collagen beads, or acetylcellulose hollow eye A carrier such as a bar is used. It is not limited to these, as long as the transformant grows under any other medium composition or culture condition.
- the sugar chain deficient type HGF thus produced in the culture supernatant of the transformant or in the transformant is known salting out method, solvent precipitation method, dialysis method, ultrafiltration method, gel electricity. Separation and purification can be carried out by combining one or more species such as electrophoresis, gel filtration chromatography, ion exchange chromatography, reversed phase chromatography and affinity chromatography, etc.
- salting out with ammonium sulfate S-sepharose ion chromatography, heparin Sepharose affinity mouth chromatography, and combination of reversed phase ephemeral phase chromatography or salting out with ammonium sulfate, S —
- a combination of sepharose ion chromatography, anti-HGF antibody sepharose affinity chromatography, etc. is preferred.
- the sugar chain-deficient HGF of the present invention can also be obtained by treating HGF with a sugar chain-removed enzyme after obtaining HGF with added sugar chains by a conventionally known method.
- a sugar chain-removed enzyme As an enzyme for removing a sugar chain, glycopeptidase F or dalycopeptidase A can be used for the purpose of removing an N-linked sugar chain. Removal of the O-linked sugar chain is achieved by one or a combination of two such as sialidase, fucosidase and O-dalicanase.
- Sugar chain removal HGF obtained by enzyme treatment can be purified by the above-mentioned purification method as a sugar chain deficient HGF of the present invention.
- the sugar chain-deficient HGF of the present invention can also be obtained using a cell-free protein synthesis system.
- the target protein is encoded using the cell extract prepared from E. coli, rabbit reticulocyte cells, wheat germ or the like, or the protein synthesis factor group contained in the cell extract.
- This refers to a system that uses the DNA or mRNA as a template to perform protein synthesis without using live cells. Since the cell extract contains a group of molecules necessary for protein synthesis such as ribosomes, tRNAs or translation factors, when an amino acid serving as an energy source and substrate such as ATP or GTP is added to this, the protein is synthesized. Ru.
- the protein synthesis factor group contained in the cell extract may be mixed and used.
- the cell-free protein synthesis system does not include the endoplasmic reticulum or the Golgi body, and therefore, does not contain DNA encoding HGF having a sugar chain having a glycosylation site or It is possible to produce sugar chain deficient HGF deficient in sugar chain by using mRNA as a template. Alternatively, DNA or mRNA in which a mutation is introduced at a glycosylation site can also be used.
- the sugar chain deficient HGF synthesized in the cell-free protein synthesis reaction solution can be purified by the above-mentioned purification method.
- the sugar chain deficient HGF of the present invention obtained as described above has an activity equivalent to that of HGF having a sugar chain in cell proliferation activity, cell migration activity or morphogenic activity, etc., and is stable in temperature stability. Is also equivalent.
- the sugar chain deficient HGF of the present invention is more stable in blood than HGF having a sugar chain.
- the sugar chain deficient HGF according to the present invention can be applied to mammals including humans (eg, dogs, cats, rats, mice, rabbits, animals, dogs, dogs, guinea pigs, etc.).
- mammals including humans (eg, dogs, cats, rats, mice, rabbits, animals, dogs, dogs, guinea pigs, etc.).
- the medicament containing the sugar chain deficient HGF of the present invention as an active ingredient has the same use as that of HGF to which a wild type sugar chain is added, for example, a therapeutic agent for liver cirrhosis, therapeutic agent for renal disease, epithelial cell proliferation promoter, anticancer agent Anti-cancer drug side effect preventive agent, lung disorder therapeutic agent, stomach 'duodenal injury therapeutic agent, cranial nerve disorder therapeutic agent, immunosuppressive side effect preventive agent, collagen degradation promoter, cartilage disorder therapeutic agent, arterial disease therapeutic agent, pulmonary fibrosis It can be used as a therapeutic agent, a liver disease therapeutic agent, a blood coagulation disorder therapeutic agent, a plasma low protein therapeutic agent, a wound therapeutic agent, a neurological disorder improving agent, a hematopoietic stem cell increasing agent or a hair growth promoting agent.
- the medicament containing the DNA encoding the sugar chain deficient HGF of the present invention can be used as a gene therapeutic drug for the above-mentioned diseases.
- the sugar chain deficient HGF of the present invention is effective as a protein drug, and is used in the form of a general pharmaceutical preparation.
- the pharmaceutical preparation containing the sugar chain deficient HGF of the present invention as an active ingredient can take various formulation forms (for example, liquid preparation, solid preparation, capsule, etc.).
- the defective HGF and the binding substance alone or together with a conventional carrier are used as injections, inhalants, satiation or oral agents, and among them, injections are preferred.
- the injection can be prepared by a conventional method, for example, after dissolving the glycosylated HGF and the binding substance in an appropriate solvent (eg, sterilized water, buffer solution, physiological saline, etc.),
- the lysate can be prepared by filtering through a filter, sterilizing it and then filling it into a sterile container.
- the content of sugar chain deficient HGF in the injection is usually adjusted to about 0.0002-3 (WZV%), preferably about 0.012 (W / V%).
- oral As the medicine, for example, it is formulated into dosage forms such as tablets, granules, fine granules, powders, soft or hard capsules, solutions, emulsions, suspensions or syrups, and these preparations are formulated It can be prepared according to the conventional method of Suppositories can also be prepared by conventional methods on a formulation using conventional bases (eg, cocoa butter, laurin butter, glucose gelatin, macrogol, witepsol etc.). Inhalants can also be prepared according to the conventional means of formulation. The sugar chain deficient HGF content in the preparation can be appropriately adjusted according to the dosage form, the disease to be applied and the like.
- bases eg, cocoa butter, laurin butter, glucose gelatin, macrogol, witepsol etc.
- Inhalants can also be prepared according to the conventional means of formulation.
- the sugar chain deficient HGF content in the preparation can be appropriately adjusted according to the dosage form, the disease to be applied and the like.
- a stabilizer be added at the time of formulation of the pharmaceutical preparation of the sugar chain deficient type HGF of the present invention.
- the stabilizing agent for example, albumin, globulin, gelatin, alanine, glycine, mannitol, gnolose, dextran, sonolebitolee, ethylene glycol and the like can be mentioned.
- the pharmaceutical preparation of the present invention may contain other additives necessary for formulation, such as solvents (eg, physiological saline, sterile purified water, water for injection, etc.), excipients (eg, fructose, D-sorbitol, Glucose, starch, crystalline cellulose, dextrin, etc., binder (eg, gelatin, corn starch, tragacanth, gum arabic etc.), solubilizing agent (eg, lauro macrogol, poisonoleate 80, polyoxyethylene hydrogenated castor oil) 60, gum arabic, sodium benzoate, etc., antioxidants (eg, L-ascorbic acid, tocoferol nore, sodium edetate, etc.), soothing agents (eg, sodium dihydroxybenzene, procaine hydrochloride, etc.) , Tonicity agents (eg, sodium chloride, glucose, D-mannitol, darcerin etc.), buffers (eg, citric acid, citric acid)
- a liquid preparation it is desirable to remove the water by cryopreservation, lyophilization, etc. for preservation.
- the freeze-dried preparation is used by adding distilled water for injection and the like at the time of use and re-dissolving.
- enteric coatings eg For capsules that are preferably coated with cellulose acetate phthalate, methacrylic acid copolymer, hydroxypropyl cellulose sulfate, carboxymethyl cellulose etc, etc., it is preferable to use enteric capsules. Ma ,.
- the pharmaceutical preparation of the present invention can be administered by an appropriate administration route depending on the form of the preparation.
- it can be administered intravenously, arterially, subcutaneously or intramuscularly in the form of injections.
- the dose is appropriately adjusted according to the patient's disease, symptoms, age, body weight, etc.
- for adults usually about 0.20 mg to 500 mg, preferably about 0.5 mg to 100 mg of HGF deficient HGF. It is appropriate to administer it once or several times a day.
- a DNA having a nucleotide sequence encoding a sugar chain-deficient HGF of the present invention is incorporated into the above vector and can also be used as a gene therapeutic agent.
- the gene therapeutic agent of the present invention is preferably produced as a complex of the above sugar chain deficient HGF gene and a gene carrier.
- the gene carrier is preferably a viral vector or a cationic gene carrier.
- virus vectors include mouse white blood virus virus vector, adenovirus vector, adeno-associated virus vector, HIV vector, Herpes simplex vector, Sendai virus vector and the like.
- cationic gene carriers include substances having an affinity to genes such as polyamino acids such as polylysine or polydiaminobutyric acid, or cationic synthetic polymers such as ribosomes and ethyleneimine.
- HGF Hepatocyte growth factor
- dHGF 5-amino acid deleted hepatocyte growth factor
- DMEM medium Dulbecco's modified eagle medium
- FCS fetal calf serum
- NaCl Sodium chloride
- PBS phosphate buffered saline
- Tween 80 polyoxyethylene (20) sorbitan monooleate
- dHGF 5-amino acid-deleted HGF
- SEQ ID NO: 3 in the sequence listing was incorporated into pCAGGS vector.
- the resulting vector (hereinafter referred to as a wild-type vector) is referred to as pCAGGS-dHGF.
- mutation vector The mutation-introduced vector (hereinafter referred to as mutation vector) was transformed into E. coli XLIO Gold competent cells, and Amp resistant colonies were picked up on LBZAmp plates. The clones of interest were screened by extracting each obtained clonogenic plasmid and analyzing the nucleotide sequence of the coding part of the sugar chain deficient HGF. Vectors in which the target mutation was introduced at 5 sites and no other mutations were confirmed were selected and used for the subsequent experiments. The resulting mutant vector is called pCAGGS-dHGF-NG.
- wild-type vector pCAGGS-dHGF and mutation vectors pCAGGS_dHGF_NG, pCAGGS-dHGF-HIG, and pCAGGS-dHGF- / 3NG were respectively transfected into COS-7 filamentous vesicles.
- COS-7 cells in fetal calf serum (FCS) in DMEM medium 10. / o was added and cultured. The cells were replaced with serum-free DMEM medium just before transfer. Transfection was performed by lipofection using Lipofectamine 2000 (Invitrogen). Six hours after the transfection, the medium was changed to DMEM containing 1% FCS, at which time heparin was added to a concentration of 1 ⁇ g / mL.
- the wild-type dHGF and the glycosylated dHGF were eluted by raising the NaCl concentration to 1 M. . Elution was performed at a flow rate of 0.4 mL / min and fractionated at 0.4 mL / tube. The fractions in which wild-type dHGF and carbohydrate-deficient dH GF were present were collected, and the state of purification was confirmed by SDS-PAGE.
- DHGF obtained by introducing a wild-type vector is COS-dHGF-WT
- a sugar chain deleted dHGF obtained by introducing a mutant vector is COS_dHGF_NG, COS-dHGF-a NG or COS_dHGF_ ⁇ NG, respectively. It is called.
- dHGF protein was also prepared by CH0 cells according to the method described in JP-A-10-191991 (referred to as CHO_dHGF-WT).
- Example 2 Using the wild-type dHGF and the sugar chain-deficient dHGF obtained in Example 1, the proliferation activity on rat liver parenchymal cells was measured.
- Hepatic parenchymal cells were separated from SD rats (8 weeks old, male) by collagenase perfusion.
- the obtained hepatocytes were suspended in Williams E (WE) medium containing 5% FCS, and seeded in culture dishes at a cell density of 30,000 Zc m 2 . After 4 hours, the medium was removed and fresh, replaced with 480 ⁇ L of WE medium (containing 5% FCS), and culture was continued. After an additional 20 hours, 20 ⁇ L of a sample solution containing wild-type dHGF and carbohydrate-deficient dHGF was added and culture was continued.
- WE Williams E
- the radioactivity value represents the amount of [ 3 H] thymidine incorporated into cells, which reflects the amount of DNA synthesis involved in cell proliferation. That is, the value of radioactivity reflects cell proliferation activity.
- the sugar chain deficient dHGF (COS_dHGF_NG) exhibited hepatocyte proliferation activity equivalent to that of wild-type dHGF (COS_dHGF_WT and CHO_dHGF—WT).
- the C ⁇ S_dHGF-HNG which lacks the ⁇ -chain sugar chain and the C ⁇ S_dHGF_j3 NG which lacks the / 3 chain sugar chain showed similar activities.
- MDCK- 3 B cells are suspended in DMEM (containing 10% FCS) and seeded at 1 X 10 4 cells / well (480 ⁇ L / well) in a 24-well plate, where wild-type dHGF and sugar chain deficient type A test sample containing 20 h of dH GF was added. After culturing at 37 ° C. for 20 hours, the presence or absence of scatter was observed with a microscope (FIG. 3).
- COS_dHGF_NG The sugar chain deficient dHGF (COS_dHGF_NG) showed cell migration activity equivalent to that of wild-type dHGF (COS_dHGF_WT and CHO_dHGF—WT).
- COS-dHGF-a NG which lacks a sugar chain of ⁇ chain
- COS_dHGF_ ⁇ NG which lacks a sugar chain of ⁇ chain showed similar activities.
- MDCK-3B cells are suspended in a collagen solution (Cellmatrix I-A, Nitta gelatin) dissolved in DMEM (containing 10% FCS) to give a solution of 5000 cells / mL, and 500 ⁇ L in a 24-well plate. Aliquoted (2500 cells / well). After gelation of collagen by incubating at 37 ° C. for 10 minutes, 480 ⁇ l of DMEM (containing 10% FCS) is overlaid and a test sample 20 ⁇ m containing wild type dHGF and sugar chain deficient dHGF L was added. After culturing at 37 ° C. for 6 days, the state of tube formation was observed with a microscope (FIG. 4).
- collagen solution Cellmatrix I-A, Nitta gelatin
- DMEM containing 10% FCS
- the sugar chain deficient dHGF (COS_dHGF_NG) is a wild-type dHGF (COS_dHGF_WT). And CHO-dHGF-WT) showed morphogenic activity equivalent. COS-dHGF-a NG which lacks the sugar chain of a chain and COS_dHGF_ ⁇ NG which lacks sugar chain of the ⁇ chain showed similar activity.
- a wild type dHGF and a sugar chain deficient dHGF sample were diluted with 50 mM Tris_HCl (pH 7.5), 0.10% Tween 80, 0.3M NaCl to a concentration of 50 ⁇ g / mL and sealed. It was placed in a container and incubated at 37 ° C. for 7 days. A portion was sampled daily and stored at -80 ° C. The residual activities of wild-type dHGF and sugar chain-deficient dHGF in the sampled solution were evaluated by examining DNA synthesis in rat hepatocytes in the same manner as in Example 2.
- the sampled solution was diluted to 125 ng / mL with PBS, 0.5% BSA, and the 20 ⁇ L was added to 480 ⁇ L of a culture solution of hepatocytes to make a final 5 ng Z mL.
- the sugar chain deficient dHGF (COS_dHGF_NG) showed the same temperature stability as wild-type dHGF (COS_dHGF_WT and CHO-dHGF-WT) (FIG. 5).
- the C ⁇ S_dHGF_a NG which lacks a sugar chain of the ⁇ chain and the C ⁇ S_dHGF_i3 NG which lacks a sugar chain of the chain also showed the same stability.
- OOOcpm 125 1-dHGF was diluted with PBS containing 0.1% BSA to make a 100 / i L solution.
- the tail vein force was also administered to ICR mice (8 weeks old, male). Blood was collected at 1 minute, 5 minutes, 15 minutes, 30 minutes, 60 minutes and 120 minutes after administration. Plasma is separated from the collected blood and The radioactivity was measured with a round-table counter to evaluate the blood stability of wild-type dHGF and carbohydrate-deficient dHGF (Fig. 6).
- COS_dHGF_NG sugar chain deficient dHGF
- COS-dHGF_NG sugar chain deficient dHGF
- CHO_dHGF-WT The sugar chain deficient dHGF (COS_dHGF_NG) has improved blood stability compared to CHO_dHGF-WT.
- COS-dHGF_WT showed an intermediate stability between COS-dHGF-NG and CHO-dHGF-WT. This was considered to be because, as shown in Example 1, COS-dHGF-WT partially lacked a sugar chain.
- the sugar chain deficient HGF of the present invention is useful as a substitute for HGF to which a sugar chain is added.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005516320A JP4716875B2 (ja) | 2003-12-16 | 2004-12-15 | 糖鎖欠損型肝細胞増殖因子 |
EP04807078A EP1695982B1 (en) | 2003-12-16 | 2004-12-15 | Glycosylation-deficient hepatocyte growth factor |
CA002549878A CA2549878A1 (en) | 2003-12-16 | 2004-12-15 | Glycosylation-deficient hepatocyte growth factor |
US10/582,973 US7741452B2 (en) | 2003-12-16 | 2004-12-15 | Glycosylation-deficient hepatocyte growth factor |
KR1020067011680A KR101203606B1 (ko) | 2003-12-16 | 2004-12-15 | 당쇄결손형 간세포 증식 인자 |
HK06113278.0A HK1093748A1 (en) | 2003-12-16 | 2006-12-04 | Glycosylation-deficient hepatocyte growth factor |
US12/722,823 US8420350B2 (en) | 2003-12-16 | 2010-03-12 | Glycosylation-deficient hepatocyte growth factor |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003418790 | 2003-12-16 | ||
JP2003-418790 | 2003-12-16 | ||
JP2003-425691 | 2003-12-22 | ||
JP2003425691 | 2003-12-22 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/582,973 A-371-Of-International US7741452B2 (en) | 2003-12-16 | 2004-12-15 | Glycosylation-deficient hepatocyte growth factor |
US12/722,823 Division US8420350B2 (en) | 2003-12-16 | 2010-03-12 | Glycosylation-deficient hepatocyte growth factor |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005058951A1 true WO2005058951A1 (ja) | 2005-06-30 |
Family
ID=34703282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/018719 WO2005058951A1 (ja) | 2003-12-16 | 2004-12-15 | 糖鎖欠損型肝細胞増殖因子 |
Country Status (7)
Country | Link |
---|---|
US (2) | US7741452B2 (ja) |
EP (1) | EP1695982B1 (ja) |
JP (1) | JP4716875B2 (ja) |
KR (1) | KR101203606B1 (ja) |
CA (1) | CA2549878A1 (ja) |
HK (1) | HK1093748A1 (ja) |
WO (1) | WO2005058951A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006009226A1 (ja) * | 2004-07-21 | 2006-01-26 | Seikagaku Corporation | アスパラギン結合型糖鎖修飾を受けない変異型糖タンパク質 |
WO2019187691A1 (ja) * | 2018-03-26 | 2019-10-03 | 株式会社カネカ | コラゲナーゼ活性を有するポリペプチド及びその製造方法 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010120511A2 (en) | 2009-03-31 | 2010-10-21 | Altair Therapeutics, Inc. | Method of treating respiratory disorders |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0418028A (ja) | 1990-05-09 | 1992-01-22 | Toshiichi Nakamura | 肝硬変治療剤 |
JPH0449246A (ja) | 1990-06-19 | 1992-02-18 | Toshiichi Nakamura | 賢疾患治療剤 |
EP0492614A2 (en) | 1990-12-28 | 1992-07-01 | NAKAMURA, Toshikazu | Epitheliocyte growth accelerator |
WO1993003061A1 (en) | 1991-07-26 | 1993-02-18 | Toray Industries, Incorporated | Hematopoietic stem cell multiplier |
WO1993008821A1 (en) | 1991-11-07 | 1993-05-13 | Toshikazu Nakamura | Side effect inhibitor for cancer therapy |
JPH05213721A (ja) | 1992-02-05 | 1993-08-24 | Sansho Seiyaku Co Ltd | 毛髪用外用剤 |
JPH0625010A (ja) | 1991-05-15 | 1994-02-01 | Toshiichi Nakamura | 抗ガン剤 |
WO1994002165A1 (en) | 1992-07-16 | 1994-02-03 | Snow Brand Milk Products Co., Ltd. | Blood coagulation normalizer containing tcf-ii as active ingredient |
JPH0640934A (ja) | 1992-07-16 | 1994-02-15 | Snow Brand Milk Prod Co Ltd | Tcf−iiを有効成分とする肝臓疾患治療剤 |
JPH0640935A (ja) | 1992-07-16 | 1994-02-15 | Snow Brand Milk Prod Co Ltd | Tcf−iiを有効成分とする蛋白合成促進剤 |
JPH0656692A (ja) | 1992-08-10 | 1994-03-01 | Snow Brand Milk Prod Co Ltd | Tcf−iiを有効成分とする創傷治療剤 |
JPH06172207A (ja) | 1992-10-08 | 1994-06-21 | Toshiichi Nakamura | 肺傷害治療剤 |
JPH0741429A (ja) | 1993-07-30 | 1995-02-10 | Mitsubishi Chem Corp | 神経障害改善薬 |
JPH0789869A (ja) | 1993-09-17 | 1995-04-04 | Toshiichi Nakamura | 脳神経障害治療剤 |
JPH07508420A (ja) * | 1992-05-18 | 1995-09-21 | ジェネンテク,インコーポレイテッド | 肝細胞成長因子変異体 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2706704B2 (ja) * | 1989-06-05 | 1998-01-28 | 敏一 中村 | 組換ヒト肝実質細胞増殖因子 |
US5316921A (en) * | 1992-05-18 | 1994-05-31 | Genentech, Inc. | Single-chain hepatocyte growth factor variants |
CA2364997A1 (en) * | 1999-03-05 | 2000-09-08 | Maxygen, Inc. | Encryption of traits using split gene sequences |
CA2410762C (en) * | 2000-05-31 | 2013-10-15 | Masashi Miyake | Feline hepatocyte growth factor |
AU7459101A (en) * | 2000-06-22 | 2002-01-02 | Nippon Zenyaku Kogyo Ltd | Canine liver cell growth factor |
US7265085B2 (en) * | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycoconjugation methods and proteins/peptides produced by the methods |
-
2004
- 2004-12-15 EP EP04807078A patent/EP1695982B1/en not_active Not-in-force
- 2004-12-15 KR KR1020067011680A patent/KR101203606B1/ko active IP Right Grant
- 2004-12-15 JP JP2005516320A patent/JP4716875B2/ja active Active
- 2004-12-15 US US10/582,973 patent/US7741452B2/en not_active Expired - Fee Related
- 2004-12-15 CA CA002549878A patent/CA2549878A1/en not_active Abandoned
- 2004-12-15 WO PCT/JP2004/018719 patent/WO2005058951A1/ja active Application Filing
-
2006
- 2006-12-04 HK HK06113278.0A patent/HK1093748A1/xx not_active IP Right Cessation
-
2010
- 2010-03-12 US US12/722,823 patent/US8420350B2/en not_active Expired - Fee Related
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0418028A (ja) | 1990-05-09 | 1992-01-22 | Toshiichi Nakamura | 肝硬変治療剤 |
JPH0449246A (ja) | 1990-06-19 | 1992-02-18 | Toshiichi Nakamura | 賢疾患治療剤 |
EP0492614A2 (en) | 1990-12-28 | 1992-07-01 | NAKAMURA, Toshikazu | Epitheliocyte growth accelerator |
JPH0625010A (ja) | 1991-05-15 | 1994-02-01 | Toshiichi Nakamura | 抗ガン剤 |
WO1993003061A1 (en) | 1991-07-26 | 1993-02-18 | Toray Industries, Incorporated | Hematopoietic stem cell multiplier |
WO1993008821A1 (en) | 1991-11-07 | 1993-05-13 | Toshikazu Nakamura | Side effect inhibitor for cancer therapy |
JPH05213721A (ja) | 1992-02-05 | 1993-08-24 | Sansho Seiyaku Co Ltd | 毛髪用外用剤 |
JPH07508420A (ja) * | 1992-05-18 | 1995-09-21 | ジェネンテク,インコーポレイテッド | 肝細胞成長因子変異体 |
WO1994002165A1 (en) | 1992-07-16 | 1994-02-03 | Snow Brand Milk Products Co., Ltd. | Blood coagulation normalizer containing tcf-ii as active ingredient |
JPH0640934A (ja) | 1992-07-16 | 1994-02-15 | Snow Brand Milk Prod Co Ltd | Tcf−iiを有効成分とする肝臓疾患治療剤 |
JPH0640935A (ja) | 1992-07-16 | 1994-02-15 | Snow Brand Milk Prod Co Ltd | Tcf−iiを有効成分とする蛋白合成促進剤 |
JPH0656692A (ja) | 1992-08-10 | 1994-03-01 | Snow Brand Milk Prod Co Ltd | Tcf−iiを有効成分とする創傷治療剤 |
JPH06172207A (ja) | 1992-10-08 | 1994-06-21 | Toshiichi Nakamura | 肺傷害治療剤 |
JPH0741429A (ja) | 1993-07-30 | 1995-02-10 | Mitsubishi Chem Corp | 神経障害改善薬 |
JPH0789869A (ja) | 1993-09-17 | 1995-04-04 | Toshiichi Nakamura | 脳神経障害治療剤 |
Non-Patent Citations (13)
Title |
---|
ADACHI E. ET AL: "Functional Analysis of Sugar Chains on NK4 (HGF antagonist/angiogenesis inhibitor)", INVASION, METASTASIS AND APOPTOSIS OF CANCER, vol. 76, no. 8, August 2004 (2004-08-01), pages 1103 - 4P-622, XP002986335 * |
AIKAWA J. ET AL: "Aspraragine-linked glycosylation of the rat leukemia inhibitory factor expressed by simian COS7 cells", BIOSCI BIOTECHNOL BIOCHEM, vol. 62, no. 7, 1998, pages 1318 - 1325, XP002986332 * |
BELLOSTA P. ET AL: "Cleavage of K-FGF produces a truncated molecule with increased biological activity and receptor binding affinity", J CELL BIOL, vol. 121, no. 3, 1993, pages 705 - 713, XP000942993 * |
BIOCHEMICA ET BIOPHYSICA ACTA, vol. 1120, 1992, pages 343 - 350 |
BJOERN S. ET AL: "Human plasma and recombinant factor VII. Characterization of O-glycosylations at serine residues 52 and 60 and effects of site-directed mutagenesis of serine 52 to alanine", J BIOL CHEM, vol. 266, no. 17, 1991, pages 11051 - 7, XP001086550 * |
DATABASE GENBANK [online] 8 November 1994 (1994-11-08), MIYAZAWA K. ET AL: "Human hepatocyte growth factor (hHGF) mRNA, complete cds", XP002986331, Database accession no. (M29145) * |
DAVIS-FLEISCHE K.M. ET AL: "Site-directed mutagenesis of heparin-binding EGF-like growth factor (HB-EGF): analysis of O-glycosylation sites and properties", GROWTH FACTORS, vol. 19, no. 2, 2001, pages 127 - 143, XP002986333 * |
FUKUTA K. ET AL: "Functional Analysis of Sugar Chains on HGF Based on Deglycosylation", SIGNALING MOLECULES, vol. 76, no. 8, August 2004 (2004-08-01), pages 1035 - 4P-214, XP002986334 * |
HARA H. ET AL: "Structural study of the N-linked oligosaccharides of hepatocyte growth factor by two-dimensional sugar mapping", J BIOCHEM (TOKYO), vol. 114, no. 1, 1993, pages 76 - 82, XP009044974 * |
HOFMANN R. ET AL: "Scatter factor is a glycoprotein but glycosylation is not required for its activity", BIOCHIM BIOPHYS ACTA, vol. 1120, no. 3, 1992, pages 343 - 350, XP002324299 * |
MATSUMOTO, K. ET AL., KIDNEY INTERNATIONAL, vol. 59, 2001, pages 2023 - 2038 |
See also references of EP1695982A4 * |
WEIDNER K.M. ET AL: "Evidence for the identity of human scatter factor and human hepatocyte growth factor", PROC NATL ACAD SCI USA, vol. 88, no. 16, 1991, pages 7001 - 7005, XP002084489 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006009226A1 (ja) * | 2004-07-21 | 2006-01-26 | Seikagaku Corporation | アスパラギン結合型糖鎖修飾を受けない変異型糖タンパク質 |
WO2019187691A1 (ja) * | 2018-03-26 | 2019-10-03 | 株式会社カネカ | コラゲナーゼ活性を有するポリペプチド及びその製造方法 |
Also Published As
Publication number | Publication date |
---|---|
JP4716875B2 (ja) | 2011-07-06 |
EP1695982A1 (en) | 2006-08-30 |
US7741452B2 (en) | 2010-06-22 |
HK1093748A1 (en) | 2007-03-09 |
US20100222274A1 (en) | 2010-09-02 |
KR20060133999A (ko) | 2006-12-27 |
EP1695982A4 (en) | 2007-01-10 |
KR101203606B1 (ko) | 2012-11-23 |
EP1695982B1 (en) | 2013-01-23 |
US8420350B2 (en) | 2013-04-16 |
US20070161549A1 (en) | 2007-07-12 |
JPWO2005058951A1 (ja) | 2008-04-17 |
CA2549878A1 (en) | 2005-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH08506247A (ja) | 組換えctla4ポリペプチドおよびその製造方法 | |
CZ386392A3 (en) | Alpha interferon | |
UA66339C2 (uk) | Зрізаний нейротрофічний фактор, що походить з лінії гліальних клітин (gdnf), молекула днк, яка кодує gdnf, вектор, що містить зазначену молекулу днк, клітина-хазяїн, спосіб виготовлення зрізаного gdnf, фармацевтична композиція та спосіб лікування | |
US8420350B2 (en) | Glycosylation-deficient hepatocyte growth factor | |
US8278270B2 (en) | HGF precursor protein variant and active protein thereof | |
CA1335360C (en) | Recombinant natural killer cell activator | |
EP0628055A1 (en) | Modified tcf | |
FI117054B (fi) | Interleukiini-15:n valmistusmenetelmä ja sitä koodaava DNA-sekvenssi | |
EP1559723B1 (en) | Use of a segment of glycosylation-deficient HGF alpha-chain | |
KR20210128517A (ko) | 변형된 인터루킨-7 단백질 및 이의 용도 | |
KR20210129282A (ko) | 변형된 인터루킨-7 단백질 및 이의 용도 | |
JP4716741B2 (ja) | 糖鎖欠損型HGFα鎖部分蛋白質 | |
WO2004087753A1 (en) | Mutein of human interferon-beta and its preparation method | |
JP3292873B2 (ja) | 組換肝実質細胞増殖因子 | |
KR100502855B1 (ko) | 인간 트롬보포이에틴 변이체 및 그의 제조방법 | |
KR20210129281A (ko) | 변형된 인터루킨-7 단백질 및 이의 용도 | |
JP3318323B2 (ja) | 組換肝実質細胞増殖因子 | |
JP2816971B2 (ja) | 組換肝実質細胞増殖因子 | |
JP2002537756A (ja) | 分泌蛋白 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480037654.6 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004807078 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005516320 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067011680 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2549878 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2004807078 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007161549 Country of ref document: US Ref document number: 10582973 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067011680 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 10582973 Country of ref document: US |